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Abstract
Superficial siderosis describes haemosiderin deposition on the surface of the brain. When present on infratentorial structures, it
can cause ataxia, sensorineural hearing loss and pyramidal signs. There is no proven treatment and patients experience slow
progression of symptoms. Iron-chelating agents have been suggested as a therapeutic option and deferiprone is suited as it crosses
the blood-brain barrier. However, deferiprone is reported to have a 1–2% risk of agranulocytosis. We performed a systematic
review on treatment of infratentorial superficial siderosis with deferiprone based on PRISMAguidelines. Studies were included if
in English or an English language translation was available, were about human subjects and referred to patients with ataxia.
Studies were excluded if they did not possess an English translation, included animal studies or did not have ataxia. Studies were
excluded if they discussed cerebral amyloid angiopathy or siderosis of other regions. Eleven papers were included. We identified
69 patients. Seventeen patients (25%) discontinued the drug. The most encountered adverse effect was anaemia (21.7%).
Neutropaenia was observed in 8.7% and agranulocytosis in 5.8% of patients. Clinically, response varied, and stability or
improvement was seen across neurological domains in 6 studies while 5 showed a mixed response. On imaging, 13 (28.9%)
patients improved, 24 (53.3%) stabilised and 8 (17.8%) deteriorated. A prospective international centralised register of patients
should be developed to inform the design and conduct of a multicentre, placebo-controlled, randomised clinical trial to evaluate
the efficacy of deferiprone. The evidence from this systematic review is that deferiprone is a promising intervention.
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Introduction
Superficial siderosis is a rare disease entity that describes the
deposition of iron-containing compounds, usually derived
from blood breakdown products in the central nervous system.
Originally described in 1908 based on pathological studies
[1], the diagnosis was made at autopsy [2]. Due to advances
in neuroimaging modalities which have a high sensitivity for
haemosiderin, superficial siderosis can be identified in vivo on
blood-sensitive magnetic resonance imaging (MRI) sequences
such as susceptibility-weighted images and T2*-gradient
recalled echo through recognising a curvilinear low signal
intensity pattern [3].
Infratentorial superficial siderosis (iSS) is classified as
haemosiderin deposition on the surface of at least two
regions of the brain: cerebellum, brainstem, cranio-
cervical junction, or spinal cord [1]. It is hypothesised to
occur due to a dural tear which causes chronic persistent
extravasation of blood into the subarachnoid space. This
may be due to a variety of underlying aetiologies such
as neurosurgery, trauma and tumours [4].
Haemosiderin deposition occurs due to the physiological
process of iron sequestration. It is a protective mechanism
which breaks down haemoglobin into haem, globin, ferritin,
bilirubin, biliverdin and free iron. This complex process
removes the toxic free iron and converts this into the less
harmful haemosiderin which is deposited on the surface of
the brain, causing loss of neurons and gliosis [5]. It is under-
stood that chronic exposure to haemosiderin may damage the
granule cells and purkinje cells [2, 6].
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The process of haemoglobin neurotoxicity has been report-
ed in vitro and in vivo studies [7, 8]. The mechanism is
hypothesised to be multifactorial due to four main processes:
oxidation, inflammation, nitric acid scavenging and oedema
[9]. This damage is not reversible, and treatment therefore
aims to halt further injury.
Clinically, this is a progressive and debilitating condition.
Patients almost invariably present with a characteristic triad of
progressive sensorineural hearing loss (95%), cerebellar atax-
ia (88%) and pyramidal signs (76%). Other signs and symp-
toms have also been described and commonly include head-
aches (37%), urinary problems (24%) and anosomia (17%),
amongst others [10].
The need for a more standardised investigation and man-
agement approach has been proposed [4]. Patients presenting
should be investigated thoroughly with brain and whole spine
MR imaging or computerised tomography (CT) myelography
to identify a possible source of bleeding. It is worth noting,
however, that the chances of finding a source of bleeding are
extremely small. If such a source is found, this can be surgi-
cally repaired to stop future leakage of blood and further
haemosiderin build-up. Alternatively, iron-chelating therapy
may be trialled.
There are presently no treatment options licensed for use.
Iron-chelating agents have been identified as a promising
treatment option. However, this is only licensed to prevent
chronic iron overload in patients with thalassaemia.
Deferiprone is uniquely suited for this purpose as it is lipid
soluble and crosses the blood-brain barrier, targeting the cen-
tral nervous system and reducing the chronic build-up of
haemosiderin, thereby stopping progression [11]. Despite this,
to date there has been no conclusive evidence that treatment
alters the disease either clinically or radiologically [4].
Moreover, there have been concerns raised about the safety
profile of deferiprone as it may cause life threatening adverse
effects such as agranulocytosis. This was first reported by
Huprikar et al. [12] in one patient after 4 months of therapy.
It has been estimated to occur in up to 1–2% [13].
The aim of this study is to systematically review the avail-
able literature on the use of deferiprone in the treatment of
infratentorial superficial siderosis by assessing the clinical




A systematic literature search based on the PRISMA guidance
was undertaken on PubMed, MEDLINE, PubMed Central
and NCBI Bookshelf on 20 April 2020. The search involved
using theMedical Subject Headings (MESH) terms described.
Term A was “chelation therapy”, “chelating agents”,
“pyridones” or “deferiprone” and Term B was “siderosis”,
“hemosiderosis” or “superficial siderosis”. The inclusion and
exclusion criteria detailed below were applied and the bibli-
ography of each selected article was assessed for further stud-
ies which were not identified via the aforementioned strategy.
Inclusion and Exclusion Criteria
To be included in the review, the following criteria had to be
met:
1. Subjects were human
2. English language or English language translation
available
3. Studies specifically referred to infratentorial/posterior fos-
sa superficial siderosis
4. Studies referred to patients with superficial siderosis pre-
senting with ataxia
5. Case reports, case series and trials
The exclusion criteria applied were as follows:
1. Studies with animal subjects
2. No English language translation available
3. Studies referring to only cortical superficial siderosis or
cerebral amyloid angiopathy
4. Studies of patients without imaging who do not have
ataxia
5. Studies not related to superficial siderosis of the central
nervous system
Results
The search strategy resulted in the identification of 194 arti-
cles. The titles and abstracts were assessed against the eligi-
bility criteria. Twelve articles met the inclusion criteria. One
article was subsequently excluded as the same patient was
reported in two separate studies [14, 15]. In total, 11 papers
were used for this review. Figure 1 demonstrates the PRISMA
diagram of study selection. Patient characteristics can be
found in Table 1. The individual study characteristics can be
found in Table 2.
Aetiology
The underlying aetiology for infratentorial superficial
siderosis is variable and may be difficult to confidently iden-
tify. The largest available study by Kessler et al. [21] did not
report all the aetiologies but noted that a dural tear was the
commonest one while many remained unknown despite
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investigation. The most common source of bleeding was due
to dural defects (11.5%). 6 patients (8.7%) had no identified
source. Less commonly 7.2% occurred post-neurosurgery,
4.3% had a CNS tumour and 2.9% had a meningocoele.
Rarer causes, each diagnosed in 1 patient, were reportedly
seen due to subarachnoid haemorrhage, vertebral artery aneu-
rysm, recurrent inner ear haemorrhage, road traffic accident
and frontal subdural.
Disease Duration
The data on the duration of illness prior to commencing treat-
ment was not routinely reported. Of those studies which
reported it, the duration of disease prior to therapy was be-
tween 6 months [24] and 276 months [12]. The average doc-
umented disease duration for positive outcomes was 77.3
months and for mixed outcomes was 115.6 months, raising
the possibility of earlier intervention providing better out-
comes for patients.
Deferiprone
Deferiprone is currently licensed for the treatment of iron
overload in patients with thalassaemia major in whom
desferrioxamine is contraindicated or is inadequate. This
iron-chelating agent was found to be safe, effective and well
Fig. 1 PRISMA chart illustrating
study selection process
Table 1 Patient characteristics
Number of iSS patients studied Total number of iSS patients across all studies (n) 69
Range of patients across all studies (n) 1–38
Mean number of patients per study (n) 6.27
Median number of patients per study (n) 1
Demographics Male:female 14:9
Mean age (years) 60.9
Imaging Patients with pre-treatment MRI (n) 69
Patients with post-treatment MRI (n) 43
Treatment Mean treatment duration (months) 24.3
Range treatment duration (months) 3–120
Median treatment duration (months) 24
Tolerability Patients who completed treatment (n) 57
Patients who withdrew from treatment (n) 12
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Case report 1 15–30
mg/kg/day
N/A 38 Clinical and
radiological
change














3 Cummins et al.
[17]
Case report 1 1000 mg three
times a day
84 12 Clinical and
radiological
change
Improved Improved Improved Stable Nil Positive













5 Schirinzi et al. [18] Case report 1 30 mg/kg/day 60 3 Clinical and
radiological
change
Improved N/A Improved Stable Nil Positive
6 Kuo et al. [19] Case report 1 15 mg/kg/day 72 6 Clinical and
radiological
change
Improved Improved Improved Improved Nil Positive
7 Derle [20] Case report 1 30 mg/kg/day N/A 9 Clinical and
radiological
change
Stable Stable Stable N/A Nil Positive
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9 Cossu et al. [22] Case series 4 15 mg/kg
twice
a day





Not documented 2 improved,
2 stable
4 improved Nil Positive
10 Levy [23] Case report 1 1500 mg twice
a day
24 120 Clinical and
radiological
change
Mixed Stable Worse Improved Nil Mixed
11 Sammaraiee et al.
[24]
Case series 10 10–30
mg/kg/day





















tolerated in multicentre safety and efficacy trials [25, 26]. It is
prescribed at a dose of 75 mg/kg/day, given 3 times a day
(rounded down to the nearest 250 mg tablet).
As deferiprone is the only agent that crosses the blood-
brain barrier, this review evaluated its use in the treatment of
superficial siderosis. The first case report on its use was pub-
lished by Levy and Llinas [14] in 2011. Due to promising
findings of improved clinical and neuroimaging features, fur-
ther studies were performed.
In infratentorial superficial siderosis, there has been varia-
tion in the treatment dose and the optimal dose remains un-
clear. Levy and Llinas [14] commenced treatment at a dose of
30mg/kg/day and subsequently reduced the dose to 15mg/kg/
day due to perceived side effects. This treatment regime has
been used in multiple other cases including a pilot safety trial
for the drug [14–16, 18, 20]. However, other treatment doses
have been reported in literature including 30mg/kg/day over 5
days [21], 15 mg/kg/day [19, 22], 10–30 mg/kg/day [24],
1000 mg twice a day for 5 days [12], 1500 mg twice a day
[23] and 1000 mg three times a day [17]. These doses are
lower than the therapeutic 75 mg/kg/day licensed use for
thalassaemia.
The reported treatment duration varied considerably. In a
case report, Levy [23] shares his experience of a single patient
who was treated for 10 years with deferiprone. The average
treatment duration was 24.3 months. However, the range of
treatment duration was between 3 months and 120 months,
with a median of 24 months.
These factors limit the interpretation of findings as higher
doses may lead to increased adverse effects which are not
experienced with lower doses [14]. This contrasts with the
known dose and side effect profile of deferiprone when used
for thalassaemia. Moreover, as different doses have been used
across studies, there remains no optimal therapeutic dose
available.
Treatment Effect—Clinical Change
The first report that identified a positive clinical change with
deferiprone was published in 2012 [15]. Following treatment
with deferiprone for 38 months, the patient reported that the
hearing loss and ataxia had resolved and at the time of publi-
cation the patient was asymptomatic. In a previous publication
on the same patient, Levy and Llinas [14] reported that his
hearing had stabilised while the ataxia had improved within
6–12 months. Clinically, 5 case reports identified improve-
ment in ataxia following treatment [12, 15, 17, 18] while only
3 patients reported a subjective improvement in hearing [15,
17, 19]. In a pilot safety trial for the use of deferiprone, Levy
and Llinas [14] were able to show that after 3 months, 4 (40%)
clinically improved, 4 (40%) were stable and only 2 (20%)
were worse. However, this trial was not designed to measure
clinical outcomes and may have introduced bias as 8 (80%)
patients self-reported the outcome.
The largest study by Kessler et al. [21] involved 38 patients
who were followed up for 2 years, with 31 completing the
clinical trial. This identified that 19 (63%) of their cohort
reported a stable or improved clinical outcome in at least
one domain (ataxia or hearing) with 40% showing a stability
in their hearing and 30% a stable or improved coordination
and walking. On the other hand, 11 (37%) identified a slow
progression of their clinical condition and overall, the results
were mixed as both positive and negative changes were seen
in individual neurological domains across patients.
Similarly, after therapy with deferiprone for 10 years, Levy
[23] reported that there was stabilisation of hearing and wors-
ening of ataxia. Moreover, in a case series no clinical improve-
ment was identified in 6 (60%) patients’ condition and 4
(40%) had deteriorated [24]. Therefore, these studies showed
that deferiprone showed promise as a medication to stop or
slow disease progression.
There were a number of limitations in these studies. One
study was not designed to monitor the clinical outcomes [16],
clinical change was not objectively assessed by a neurologist
in 2 studies [12, 23] while Kessler et al. [21] reported both
objective and subjective assessments [1, 6, 10, 13, 21]. As
studies are largely case reports, these findings may not be
generalisable. Furthermore, there had been many patients
who had stopped taking treatment due to adverse effects or
due to the cost of the drug [21, 24]. Lastly, outcome measures
were inconsistent as no standardised reporting protocol had
been used and changes were identified as overall difference as
well as domains (ataxia and hearing impairment).
Treatment Effect—Radiological Change
Out of the 45 patients who had repeated magnetic resonance
imaging across 11 studies, 13 (28.9%) showed subjective ra-
diological improvement, 24 (53.3%) showed no change and 8
(17.8%) showed a deterioration. One study did not reportMRI
findings after treatment [20]. In the largest study, Kessler et al.
[21] report that only 16 (42.1%) of 38 patients completed the
trial with an MRI.
Reporting of imaging modalities was found to be poor.
MRI field strengths were only reported in 2 of the studies
and one of these used both 1.5 T and 3 T on the same patient
which may account for the lack of improvement as
haemosiderin deposits that was not previously identified
may now be seen [16, 22]. The included studies were noted
to use different MRI sequences and protocols. Six studies
were found to use blood-sensitive MRI sequences (suscepti-
bility-weighted images and T2* gradient recalled echo) [15,
19, 21, 22, 24]. Three only used T2 sequences [12, 16, 17].
Three did not report imaging modalities [18, 20, 23].
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Cossu et al. [22] reported that the MRI findings varied on 6
monthly follow-up and although unchanged at 6 months, by
12 months 2 patients were found to have a reduction in
haemosiderin deposition and this improvement persisted up
to 60 months. This raises the issue of whether patients in other
studies have not been followed up for an appropriate length of
time to appreciate the radiological changes.
This review is limited as not all patients had repeated MRI
sequences after treatment. Only one of the studies used single
blinded evaluation by the reporting radiologist [22]. There
was also no standardised timescale for repeat neuroimaging
follow-up. Moreover, at present, there is no validated quanti-
tative method to identify the amount of haemosiderin deposi-
tion on MRI and the reporting seen in these studies is subjec-
tive and observer-dependent. Lastly, only 2 studies used mul-
tiple imaging assessors [22, 24]. Due to this, radiological
changes must be interpreted with caution.
Adverse Effects
Two observational studies designed to monitor side effects
and the safety of deferiprone were available. Levy and
Llinas [16] reported that patients who received the drug for
3 months were monitored with monthly blood tests. Iron de-
ficiency anaemia developed in all patients and 3 developed
abnormal liver function tests. Of note, Levy and Llinas [16]
may have introduced a selection bias as he excluded patients
who had previously experienced similar adverse effects.
Similarly, Cossu et al. [22] reported that in his cohort, no
adverse effects were present, and the drug was well tolerated.
Significant concerns regarding agranulocytosis were raised
in a case report by Huprikar et al. [12]. A patient developed a
total neutrophil count of 0 after 4 months of therapy and 3
months of unremarkable biochemical monitoring. This is the
only documented case which required multiple prolonged in-
tensive care unit admissions [12].
When taking into account all available studies, iron deficien-
cy anaemia was the most common side effect in 15 (21.7%)
patients [15, 16, 24]. This was closely followed by fatigue in
12 (17.4%). Other less commonly seen side effects included
heavy metal deficiencies (7.2%), joint pain (4.3%), abnormal
liver function tests (4.3%) and mouth sores (2.9%). Kessler
et al. [21] report that fatigue appeared to be dose-dependent.
The more serious side effects of neutropaenia and agranu-
locytosis were present in 6 patients (8.7%) and 4 patients
(5.8%) respectively. All 4 patients with an identified agranu-
locytosis were previously found to be neutropaenic clearly
showing the importance of close monitoring for adverse
events. Out of the 6 patients who developed a neutropaenia,
5 of them were re-challenged with deferiprone and in these 3
cases, agranulocytosis (defined as an absolute neutrophil
count of 0.5 × 109/L or lower), occurred [24]. Two patients
did not progress despite re-challenging with treatment [21].
This is greater than the 1–2% risk of agranulocytosis previ-
ously reported [13]. Two patients benefited from treatment
with granulocyte colony stimulating factor (GCSF) [12, 24].
The length of deferiprone therapy prior to neurotropaenia
was not documented individually and cannot be confidently
assessed. Time for neutrophil recovery for all patients varied
between 0.33 and 3 months. However, this is partly confound-
ed by the prescription of GCSF in 2 individuals [12, 24].
Onset of adverse effects after commencing treatment was
not routinely documented in the studies. From the limited
literature available, these side effects were not related to du-
ration of treatment. While the identification through routine
monitoring was detected as early as 90 days in one study [16],
one patient presented with a neutropaenic sepsis after 30
months [24]. Similarly, one patient exhibited no side effects
after 10 years [23].
The reported adverse effects were most commonly seen
within the same studies. All patients who experienced heavy
metal deficiencies and mouth sores were identified by Kessler
et al. [21]. Similarly, in the pilot study, Levy and Llinas [16]
reported all ten 10 patients experienced iron deficiency which
made up 66% of the total reported cases. Deranged liver func-
tion tests were only seen in this study. It is important to note
that the increase from 1 to 4 patients with agranulocytosis is
due to one retrospective study rather than a common finding
across all studies [24]. On the other hand, the 6 cases of
neutropaenia were reported across three studies [12, 21, 24].
The adverse effects documented varied from the known re-
ported side effect profile of deferiprone [27]. Most commonly,
nausea, vomiting or abdominal pain were experienced by 33%
of patients. None of the 69 patients in our review developed
these adverse effects. Arthralgia was seen in 15% of patients
with thalassaemia and 4.35% of patients with siderosis. This
may be due to the lower dose used. Neutropaenia was present
in 9.1% and 8.7% respectively. On the other hand, fatigue was
only witnessed in superficial siderosis.
These studies are also limited as monitoring protocols for
adverse effects were either not reported or found to be incon-
sistent across the available literature. When used in thalassae-
mia, the European Medicines Agency advises weekly full
blood counts for the first year of treatment and may be extend-
ed thereafter on a patient to patient basis [28]. Of the reported
protocols, only five studies reported commencingwith weekly
full blood counts with decreasing regularity after this period
[12, 15, 16, 22, 24]. One study reported monthly bloods tests
[21]. Five studies did not report the frequency of biochemical
monitoring [17–20, 23]. Due to this, adverse effects may be
identified and acted upon late.
Tolerability
Of the reported cases, 12 (17.4%) of patients discontinued
treatment. Of these, 5 (7.2%) were due to neutropaenia, 4
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(5.8%) due to cost, 1 (1.5%) due to agranulocytosis, 1 (1.5%)
due to fatigue and 1 (1.5%) due to complications related to
another medical illness. However, in some cases, treatment
was discontinued out of caution due to reduced neutrophil
count and re-challenged despite neutrophils returning to base-
line [21].
This study has several important factors to highlight. A key
strength of this study was that the protocol was established
prior to commencing the review process and was registered
prospectively on PROSPERO. As this is a review of the avail-
able literature, the risks of a publication bias should be ac-
knowledged. There are only three trials of 10 or more patients,
and the results may be skewed in favour of these results over
smaller case studies and series. Furthermore, as this is a retro-
spective study, the data collected relies on the published ma-
terial which may be incomplete. One should note that this was
a heterogenous population with varying aetiologies, disease
and treatment durations which precludes a meta-analysis.
Conclusions
This review identified a rather limited literature on deferiprone
in the treatment of infratentorial superficial siderosis. The
methodology used in each study was different and reporting
of outcome measures found to be inconsistent. There was only
one large-scale observational study thus interpretation of re-
sults should be made with caution and drawing conclusions
from the cohort as a whole remains limited.
Furthermore, it is clear that evidence for clinical and radio-
logical change can take a few months to years to develop and
it is not known whether radiological severity is correlated with
clinical severity. As these studies are largely short-term 6-12-
month case reports, the outcomes are more likely to be nega-
tive. Similarly, as disease duration is often not reported for
individual patients, the timing between onset of symptoms
and treatment could not be identified. This raises the question
of whether early intervention would be more beneficial to
patients.
Overall, deferiprone appeared to be well tolerated and dis-
continuation was due to mainly limited experience as well as
other unrelated conditions. However, the results showed that
in some cases deferiprone can be successfully used for the
treatment of infratentorial superficial siderosis to achieve clin-
ical and radiological stability and in some cases improvement.
This should be coupled with close monitoring of the patient’s
full blood count, haematinics and trace minerals to ensure
adverse effects are identified and acted upon. Due to the rarity
of the condition and treatment, we also advise ensuring pa-
tients are educated on the possible effects to identify and guide
their treating physicians to the important but lesser known
adverse effects.
Ideally, large-scale, multicentre, placebo-controlled,
randomised studies should be performed using a standardised
protocol which includes treatment dose, duration of follow-up
and outcome measures (audiometry, scale for the assessment
and rating of ataxia (SARA) scores and adverse effect moni-
toring) to provide further evidence of the role of deferiprone in
the treatment of infratentorial superficial siderosis. There is
also a need for further detailed stratification of patients to
accurately identify factors which alter patient outcomes such
as underlying cause of superficial siderosis, disease duration
and severity. Moreover, a prospective international centralised
register of patients should be developed which could inform
the design and conduct of a multicentre, placebo-controlled,
randomised clinical trial to evaluate the efficacy of
deferiprone.
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